ASYMCHEM
Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe. Asymchem will continue to operate the site in Sandwich, Kent, as a clinical small molecule development and manufacturing facility to meet global client demands for pharma services and supply.
The development laboratories are expected to begin operation in June 2024, followed by the API pilot plant in August. The site is expected to employ approximately 100 individuals by the end of 2024, including many staff previously employed by Pfizer. Planned additions for the site include capabilities for the manufacture of peptides and oligonucleotides, as well as sustainability capabilities utilizing continuous flow and biocatalysis.
“We are excited to become a part of the European pharma manufacturing community,” said Chairman and CEO of Asymchem Group, Dr. Hao Hong. “Meeting the needs of our clients in bringing manufacturing into the Western market will continue to be part of our long-term strategy to meet overall global business demands.”
Mayer Schreiber, CEO of Discovery Park, said: “We are delighted to welcome Asymchem to Discovery Park this summer. The organisation has selected Discovery Park as their European base and home to their first manufacturing facility in Europe, bringing new jobs and safeguarding scientific talent. Asymchem joins a burgeoning community of over 160 companies in a designated Life Sciences Opportunity Zone, representing an incredible talent pool which contributes significantly to the U.K. life sciences economy.”
About Asymchem
Asymchem is a global technology-driven contract development and manufacturing organization (CDMO) providing services to the pharmaceutical industry. Founded in 1997, Asymchem employs over 9300 personnel world-wide, with R&D and manufacturing operations in China and the U.S.
Forward-Looking Statements
This press release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, without limitation, future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.
The Company, its directors and the employees assume (a) no obligation to correct or update the forward-looking statements contained in this announcement; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.
About Discovery Park
Discovery Park is a thriving UK life science community for visionary entrepreneurs and leaders. Within easy reach of London, Discovery Park spearheads Kent’s flourishing science and technology cluster.
Discovery Park offers state-of-the-art labs, modern offices and manufacturing facilities, unrivalled flexibility and comprehensive support including access to finance and a strong local talent pool.
Discovery Park has been a major centre for life science for nearly 70 years and is home to 160+ companies across a growing tenant community of dynamic start-ups through to global corporations. This includes Algaecytes, Canterbury Christ Church University, Concept Life Sciences, eXroid, Genea Biomedx, LGC, Pfizer, Psyros Diagnostics, Salvensis, Viatris, VisusNano and Wren Healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521088343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Launches Tariff Response Solution to Help Supply Chains Adapt to Disruption with Confidence17.4.2025 19:30:00 CEST | Press release
New solution simulates tariff impacts, aligns teams, and enables action in under three weeks As ongoing tariff pressures and trade uncertainty continue to reshape global supply chains, Kinaxis® (TSX:KXS), the leader in real-time supply chain orchestration, today launched Kinaxis Tariff Response - a new offering that helps companies simulate tariff exposure, run strategic scenarios, and make data-informed decisions quickly. Built on the company’s AI-powered Maestro™ platform and delivered by Kinaxis supply chain experts, the service can be live in as few as 21 days, giving planners access to tariff modeling without the cost or complexity of building it internally. The solution meets rising demand for scenario planning - providing a faster, more accessible way for companies to shift from reactive firefighting to proactive orchestration. While AI-powered what-if scenario planning has long been a core capability of Maestro, Kinaxis Tariff Response builds on that foundation with a focused s
Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development17.4.2025 17:00:00 CEST | Press release
Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc. (headquarters: Osaka; President & Representative Director: Keitaro Iwaki; hereinafter “SPERA PHARMA”) have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417047994/en/ Left: Keitaro Iwaki, President & Representative Director, SPERA PHARMA; Right: Jun Kawakami, President & CEO, Rigaku SPERA PHARMA will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development. The XtaLAB Synergy-ED incorporates 3D ED/MicroED1, which is utilized for the structu
CORRECTING and REPLACING MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine17.4.2025 15:36:00 CEST | Press release
MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars. Seventh paragraph, first sentence should read: Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. (instead of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technolo
MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine17.4.2025 15:36:00 CEST | Press release
MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars. MultiSafepay (MSP), an Amsterdam-based payment service provider, which became part of Ant International’s Antom, reported strong growth since its strategic integration with Antom, supporting thousands more SMEs in Europe to scale through innovative solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/ Ant International’s new office in Amsterdam City Centre will hous
Avania Strengthens Leadership Team With Pivotal Executive Appointments17.4.2025 15:00:00 CEST | Press release
Avania — the leading global MedTech advisory and clinical development partner — today announced the appointments of Jasmine Saba as sr. vice president of strategic relationships and Josh Blacker as sr. vice president of global business development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417247152/en/ Jasmine Saba (left) has been appointed Sr. Vice President of Strategic Relationships. Josh Blacker (right) joins Avania as Sr. Vice President of Global Business Development. Saba Appointed Sr. Vice President of Strategic Relationships Saba will take on this new role to support Avania’s growth by identifying, building, and nurturing key partnerships with global multinational medical technology companies. She will develop repeatable and scalable solutions leveraging Avania’s partnership approach as these customers increasingly rely on Avania to be an extension of their existing teams. With her extensive experience in R&
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom